藥物基因體學技術市場－全球產業規模、佔有率、趨勢、機會和預測：按治療領域、技術、地區和競爭格局分類，2021-2031年

全球藥物基因體學技術市場預計將從 2025 年的 68.7 億美元大幅成長至 2031 年的 112.5 億美元，複合年成長率為 8.57%。

這項技術包括診斷工具、檢測試劑盒和生物資訊軟體，用於分析影響個別藥物反應的基因變異。其主要成長要素包括：需要複雜治療方案的慢性疾病在全球日益普遍，以及監管機構日益重視利用精準醫療來最大限度減少藥物不良反應。此外，製藥公司正在將生物標記分析納入臨床試驗，以提高藥物的安全性和有效性。個人化醫療聯盟的數據顯示，到2025年，個人化醫療將占美國食品藥物管理局（FDA）核准的新治療分子實體的約38%，凸顯了業界和監管機構對這些技術的大力支持。

然而，儘管成長勢頭強勁，但市場仍面臨諸多挑戰。其中一個挑戰是缺乏統一的基因檢測保險報銷機制。由於私人和公共保險公司之間缺乏統一的保險覆蓋政策，導致醫療服務提供者的財務狀況不穩定，進而阻礙了藥物基因體學檢測的常規應用，並限制了其在臨床環境中的廣泛推廣。

市場促進因素

腫瘤學領域藥物基因體學的日益普及正對該市場產生顯著影響。臨床醫生擴大利用基因譜分析來實現癌症治療的個人化。這項技術能夠檢測特定的腫瘤和生殖系突變，有助於預測藥物療效。因此，無效處方和不良副作用得以減少。製藥公司正積極將這些功能整合到其產品中，以推動精準腫瘤學解決方案的發展。例如，Exact Sciences公司在其2025年2月發布的2024年第四季及全年財報中指出，其精準腫瘤學業務部門2024年全年銷售額達到6.55億美元，凸顯了這些診斷工具的巨大商業性潛力。此外，臨床試驗中對患者進行分層以確保治療方案與最敏感的基因譜精準匹配的需求不斷成長，也進一步推動了這一趨勢。

同時，次世代定序(NGS) 和診斷技術的進步顯著降低了成本並縮短了結果返回時間，使藥物基因體學更易於普及。高通量定序平台的演進使得全面的基因組分析不再侷限於專業研究，而是成為常規臨床應用的可行選擇。 Frontline Genomics 在 2025 年 3 月報道稱，Illumina 公司宣布，到 2024 年，其全基因測序的成本將低至每個基因組 200 美元。這項進步提高了大規模人群檢測的經濟可行性。更廣泛的生態系統也為這一成長提供了支持，例如英國政府在 2025 年 7 月宣布投資高達 6 億英鎊，用於建立一個整合基因組和臨床數據的先進健康數據平台。這將進一步將藥物基因體學基礎設施融入國家醫療保健系統。

市場挑戰

缺乏統一的基因檢測報銷框架是全球藥物基因體學技術市場發展的一大障礙。由於私人和公共保險公司缺乏標準化的福利政策，醫療機構和診斷實驗室面臨巨大的財務不確定性。這種不可預測的支付狀況常常迫使醫療機構限制藥物基因體學學設備和檢測套組的使用，因為他們無法保證從這些專業服務中獲得收入。因此，臨床醫生往往不願意常規申請這些檢測，儘管精準醫療具有公認的臨床優勢，但實際上卻阻礙了其融入標準患者照護。

近期行業統計數據凸顯了這一財務障礙的嚴重性，這些數據揭示了支付方面面臨的挑戰。美國藥物基因體學協會報告稱，到2025年，提交的藥物基因體學檢測申請的總報銷率僅為46%。這項統計數據表明，不到一半的診斷申請能夠獲得支付，這給許多實驗室造成了經濟上難以持續的困境。如此高的拒付率直接阻礙了對新型生物資訊軟體和檢測基礎設施的投資，從而限制了市場的進一步商業性成長。

市場趨勢

人工智慧 (AI) 和機器學習在基因組數據解讀中的融合正在改變市場。這解決了分析海量多體學資料集的難題。與傳統人工方法處理多基因風險評分時常遇到的困難相比，AI 演算法能夠快速識別複雜的基因-藥物交互作用，並高精度地預測治療結果。這項能力解決了基因組數據快速成長所帶來的瓶頸問題。這項技術進步對於將其應用於臨床實踐至關重要，因為它提高了處方建議的可靠性，超越了傳統指南。美國藥理基因組學 (ASPG) 在 2025 年 12 月發布的《2025 年藥理基因組學領域最重大進展——年度檢驗》中提及的 AI 工具“Sherpa Rx”的一項驗證研究表明，該模型在複雜的藥理基因組學查詢中達到了 90% 的準確率，顯著優於語言模型的大規模語言模型。

同時，預防性藥物基因體學篩檢模式的興起標誌著從被動檢測到主動、全人群調查方法的策略轉變。醫療系統正擴大啟動試驗計畫，在患者需要用藥前進行基因分型，確保電子健康記錄中患者的基因數據能夠持續訪問，從而輔助後續的處方決策。這種方法已獲得廣泛的公眾支持，這對其在腫瘤專科以外的領域廣泛應用至關重要。倫敦瑪麗皇后大學2025年2月發表於《藥學雜誌》的一項調查顯示，89%的受訪者對藥物基因檢測在提高藥物療效和減少副作用方面的應用持正面態度。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球藥物基因體學技術市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 治療領域（腫瘤科（肺癌、乳癌、大腸癌、子宮頸癌等）、神經系統疾病、心血管疾病、免疫系統疾病、感染疾病等）
  • 透過技術（PCR、原位雜合反應、免疫組織化學、定序等）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美藥物基因體學技術市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲藥物基因體學技術市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區藥物基因體學技術市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲藥物基因體學技術市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲藥物基因體學技術市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章：全球藥物基因體學技術市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Illumina, Inc.
• Thermo Fisher Scientific Inc.
• F. Hoffmann-La Roche Ltd.
• QIAGEN NV
• Agilent Technologies, Inc.
• Abbott Laboratories, Inc.
• Bio-Rad Laboratories, Inc.
• Myriad Genetics, Inc.
• 23andMe Holding Co.
• Becton, Dickinson and Company

第16章 策略建議

第17章：關於研究公司及免責聲明

The global pharmacogenomics technology market is projected to expand significantly, from USD 6.87 billion in 2025 to USD 11.25 billion by 2031, demonstrating an 8.57% Compound Annual Growth Rate. This technology involves diagnostic tools, assay kits, and bioinformatics software used to analyze genetic variations impacting individual responses to drugs. Key growth drivers include the increasing global incidence of chronic diseases, which necessitate intricate medication plans, and a growing regulatory emphasis on using precision medicine to minimize adverse drug reactions. Additionally, pharmaceutical companies are integrating biomarker analysis into clinical trials to boost drug safety and effectiveness. Data from the Personalized Medicine Coalition indicates that personalized medicines constituted around 38% of new therapeutic molecular entities approved by the U.S. FDA in 2025, highlighting robust industry and regulatory support for these advancements.

However, despite these positive growth trajectories, the market encounters a substantial obstacle: the inconsistent reimbursement environment for genetic testing. The absence of uniform coverage policies across both private and public payers generates financial instability for healthcare providers, often discouraging the routine use of pharmacogenomic tests and hindering their wider clinical adoption.

Market Driver

The market is being significantly influenced by the increasing use of pharmacogenomics in oncology, where clinicians are more frequently employing genetic profiling to customize cancer therapies. This method enables the detection of specific tumor mutations and germline variants, which helps predict drug effectiveness, consequently reducing ineffective prescriptions and adverse toxicities. Pharmaceutical firms are actively incorporating these functionalities into their offerings to advance precision oncology solutions. For example, Exact Sciences Corp. reported $655 million in Precision Oncology revenue for the full year 2024, as noted in their February 2025 'Fourth Quarter and Full Year 2024 Results', underscoring the considerable commercial scope of these diagnostic tools. This trend is further amplified by the increasing need for patient stratification in clinical trials to ensure treatments align with the most responsive genetic profiles.

Simultaneously, progress in next-generation sequencing (NGS) and diagnostic technologies is making pharmacogenomics more accessible by substantially cutting costs and speeding up turnaround times. High-throughput sequencing platforms have evolved, making comprehensive genomic profiling viable for routine clinical applications, moving beyond solely specialized research. Frontline Genomics reported in March 2025 that Illumina stated in 2024 it could achieve whole genome sequencing for as little as $200 per genome, a development that improves the economic feasibility of large-scale population testing. This growth is also fueled by broader ecosystem support, as evidenced by the UK Government's July 2025 announcement of an investment of up to £600 million for an advanced health data platform integrating genomic and clinical data, thereby further embedding pharmacogenomic infrastructure into national healthcare systems.

Market Challenge

The inconsistent reimbursement framework for genetic testing poses a significant hurdle to the global pharmacogenomics technology market. When private and public payers lack standardized coverage policies, healthcare providers and diagnostic laboratories encounter considerable financial uncertainties. This unpredictable payment scenario frequently forces medical facilities to restrict the uptake of pharmacogenomic instruments and assay kits, as they cannot ensure revenue for these specialized services. Consequently, clinicians often become reluctant to routinely order these tests, effectively impeding the integration of precision medicine into standard patient care despite its established clinical advantages.

The severity of this financial impediment is highlighted by recent industry figures demonstrating the challenges in securing payments. The American Pharmacogenomics Association reported in 2025 that the total reimbursement rate for submitted pharmacogenomic testing claims was merely 46 percent. This statistic reveals that less than half of these diagnostic claims were paid, fostering an economically unsustainable environment for numerous laboratories. Such elevated denial rates directly deter investment in novel bioinformatics software and testing infrastructure, thereby limiting the market's wider commercial growth.

Market Trends

The market is being transformed by the integration of Artificial Intelligence and Machine Learning for genomic data interpretation, which addresses the challenges of analyzing extensive multi-omics datasets. In contrast to conventional manual methods that often struggle with polygenic risk scores, AI algorithms can swiftly pinpoint complex gene-drug interactions and forecast therapeutic outcomes with high accuracy. This capability resolves a bottleneck stemming from the rapid growth of genomic data. This technological advancement is crucial for clinical integration, as it improves the dependability of prescribing recommendations beyond conventional guidelines. A validation study of the AI tool Sherpa Rx, mentioned by the American Pharmacogenomics Association in December 2025's 'The Biggest Pharmacogenomics Advances of 2025 - Year in Review', demonstrated that the model achieved 90 percent accuracy in responding to intricate pharmacogenomic inquiries, significantly surpassing standard large language models.

Concurrently, the rise of preemptive pharmacogenomic screening models signals a strategic pivot from reactive testing towards a proactive, population-wide methodology. Healthcare systems are increasingly initiating pilot programs where patients undergo genotyping prior to needing medication, ensuring their genetic data is consistently accessible within electronic health records to inform subsequent prescribing choices. This approach is garnering significant public acceptance, which is vital for its widespread adoption beyond specialized oncology contexts. A survey by Queen Mary University of London, reported in The Pharmaceutical Journal in February 2025, found that 89 percent of respondents were amenable to pharmacogenomic testing to enhance drug efficacy and mitigate side effects.

Key Market Players

• Illumina, Inc.
• Thermo Fisher Scientific Inc.
• F. Hoffmann-La Roche Ltd.
• QIAGEN N.V.
• Agilent Technologies, Inc.
• Abbott Laboratories, Inc.
• Bio-Rad Laboratories, Inc.
• Myriad Genetics, Inc.
• 23andMe Holding Co.
• Becton, Dickinson and Company

Report Scope

In this report, the Global Pharmacogenomics Technology Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Pharmacogenomics Technology Market, By Therapeutic Area

• Oncology
• Neurological Disorders
• Cardiovascular Disease
• Immunological Disorders
• Infectious Diseases
• Others

Pharmacogenomics Technology Market, By Technology

• PCR
• In-situ Hybridization
• Immunohistochemistry
• Sequencing
• Others

Pharmacogenomics Technology Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Pharmacogenomics Technology Market.

Available Customizations:

Global Pharmacogenomics Technology Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Pharmacogenomics Technology Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Therapeutic Area (Oncology ( lung Cancer, Breast Cancer, Colorectal Cancer, Cervical Cancer, Others), Neurological Disorders, Cardiovascular Disease, Immunological Disorders, Infectious Diseases, Others)
  • 5.2.2. By Technology (PCR, In-situ Hybridization, Immunohistochemistry, Sequencing, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2025)
• 5.3. Market Map

6. North America Pharmacogenomics Technology Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Therapeutic Area
  • 6.2.2. By Technology
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Pharmacogenomics Technology Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Therapeutic Area
      • 6.3.1.2.2. By Technology
  • 6.3.2. Canada Pharmacogenomics Technology Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Therapeutic Area
      • 6.3.2.2.2. By Technology
  • 6.3.3. Mexico Pharmacogenomics Technology Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Therapeutic Area
      • 6.3.3.2.2. By Technology

7. Europe Pharmacogenomics Technology Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Therapeutic Area
  • 7.2.2. By Technology
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Pharmacogenomics Technology Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Therapeutic Area
      • 7.3.1.2.2. By Technology
  • 7.3.2. France Pharmacogenomics Technology Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Therapeutic Area
      • 7.3.2.2.2. By Technology
  • 7.3.3. United Kingdom Pharmacogenomics Technology Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Therapeutic Area
      • 7.3.3.2.2. By Technology
  • 7.3.4. Italy Pharmacogenomics Technology Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Therapeutic Area
      • 7.3.4.2.2. By Technology
  • 7.3.5. Spain Pharmacogenomics Technology Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Therapeutic Area
      • 7.3.5.2.2. By Technology

8. Asia Pacific Pharmacogenomics Technology Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Therapeutic Area
  • 8.2.2. By Technology
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Pharmacogenomics Technology Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Therapeutic Area
      • 8.3.1.2.2. By Technology
  • 8.3.2. India Pharmacogenomics Technology Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Therapeutic Area
      • 8.3.2.2.2. By Technology
  • 8.3.3. Japan Pharmacogenomics Technology Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Therapeutic Area
      • 8.3.3.2.2. By Technology
  • 8.3.4. South Korea Pharmacogenomics Technology Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Therapeutic Area
      • 8.3.4.2.2. By Technology
  • 8.3.5. Australia Pharmacogenomics Technology Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Therapeutic Area
      • 8.3.5.2.2. By Technology

9. Middle East & Africa Pharmacogenomics Technology Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Therapeutic Area
  • 9.2.2. By Technology
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Pharmacogenomics Technology Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Therapeutic Area
      • 9.3.1.2.2. By Technology
  • 9.3.2. UAE Pharmacogenomics Technology Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Therapeutic Area
      • 9.3.2.2.2. By Technology
  • 9.3.3. South Africa Pharmacogenomics Technology Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Therapeutic Area
      • 9.3.3.2.2. By Technology

10. South America Pharmacogenomics Technology Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Therapeutic Area
  • 10.2.2. By Technology
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Pharmacogenomics Technology Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Therapeutic Area
      • 10.3.1.2.2. By Technology
  • 10.3.2. Colombia Pharmacogenomics Technology Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Therapeutic Area
      • 10.3.2.2.2. By Technology
  • 10.3.3. Argentina Pharmacogenomics Technology Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Therapeutic Area
      • 10.3.3.2.2. By Technology

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Pharmacogenomics Technology Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Illumina, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Thermo Fisher Scientific Inc.
• 15.3. F. Hoffmann-La Roche Ltd.
• 15.4. QIAGEN N.V.
• 15.5. Agilent Technologies, Inc.
• 15.6. Abbott Laboratories, Inc.
• 15.7. Bio-Rad Laboratories, Inc.
• 15.8. Myriad Genetics, Inc.
• 15.9. 23andMe Holding Co.
• 15.10. Becton, Dickinson and Company

16. Strategic Recommendations

17. About Us & Disclaimer